Skip to main content
TCRT logo

Alaunos Therapeutics, Inc.

TCRTNASDAQHealthcareBiotechnology

$2.63Today:- (-)1Y −28.99%

As of Oct 16, 2026 close

Market cap
$5.30M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.72$4.50
Volume (live)
-
Avg. volume (3M)
14.27M

Alaunos Therapeutics (TCRT) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Alaunos Therapeutics, Inc.
TCRT•Nasdaq Stock Market•Healthcare•Biotechnology

About Alaunos Therapeutics

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Company Information

CEOHolger Weis
Founded2003
Employees1
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone346 355 4099
Address
501 E. Las Olas Blvd., Suite 300 Fort Lauderdale, Florida 33301 United States

Corporate Identifiers

CIK0001107421
CUSIP98973P101
ISINUS98973P3091
EIN84-1475642
SIC2834

Leadership Team & Key Executives

Holger Weis CPA
Chairman of the Board and Chief Executive Officer
Ferdinand Groenewald
Vice President of Finance and Corporate Secretary